The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium
Copyright © 2022. Published by Elsevier Masson SAS..
BACKGROUND/AIMS: Arsenic trioxide (ATO) is an effective anti-cancer drug. Nonetheless, it possesses cardiotoxic effects which limit its clinical application. The present study aims to elucidate the molecular basis of ATO-induced cardiotoxicity through using whole transcriptome analysis.
METHODS: The whole transcriptome in ATO-treated mice myocardium was analyzed using RNA sequencing technique. These results were confirmed by real-time PCR. The lncRNA-mRNA and circRNA-mRNA co-expression networks were constructed. Finally, a circRNA-lncRNA co-regulated competing endogenous RNA (ceRNA) network was constructed. GO and KEGG pathway analyses were performed. The expression levels of Txnip and Spp1 in ATO-treated neonatal mouse cardiomyocytes were validated by real-time PCR.
RESULTS: A total of 113 mRNAs, 159 lncRNAs, 35 miRNAs, and 94 circRNAs were differentially expressed in ATO-treated mice myocardium. A lncRNA-circRNA co-regulation network was constructed. Function annotation revealed that aberrantly expressed genes may be enriched in the 'Wnt signaling pathway', 'Hippo signaling pathway', 'Notch signaling pathway', etc. Finally, the expression levels of Txnip and Spp1 were validated in ATO-treated cardiomyocytes, which was in accordance with the RNA-sequencing results.
CONCLUSION: ATO altered coding and noncoding RNA profiles in myocardium of mice. The ATO-related lncRNA-circRNA co-regulation network was constructed. Genes in the co-regulation network are likely to play important roles in the cardiotoxicity of ATO. This study provides new insights into the prevention and treatment of ATO-induced cardiotoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 151(2022) vom: 21. Juli, Seite 113183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Yanan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Arsenic Trioxide |
|---|
| Anmerkungen: |
Date Completed 10.06.2022 Date Revised 10.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2022.113183 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341985538 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341985538 | ||
| 003 | DE-627 | ||
| 005 | 20231226013030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.113183 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341985538 | ||
| 035 | |a (NLM)35676786 | ||
| 035 | |a (PII)S0753-3322(22)00572-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Yanan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The whole transcriptome analysis and the circRNA-lncRNA network construction in arsenic trioxide-treated mice myocardium |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2022 | ||
| 500 | |a Date Revised 10.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Masson SAS. | ||
| 520 | |a BACKGROUND/AIMS: Arsenic trioxide (ATO) is an effective anti-cancer drug. Nonetheless, it possesses cardiotoxic effects which limit its clinical application. The present study aims to elucidate the molecular basis of ATO-induced cardiotoxicity through using whole transcriptome analysis | ||
| 520 | |a METHODS: The whole transcriptome in ATO-treated mice myocardium was analyzed using RNA sequencing technique. These results were confirmed by real-time PCR. The lncRNA-mRNA and circRNA-mRNA co-expression networks were constructed. Finally, a circRNA-lncRNA co-regulated competing endogenous RNA (ceRNA) network was constructed. GO and KEGG pathway analyses were performed. The expression levels of Txnip and Spp1 in ATO-treated neonatal mouse cardiomyocytes were validated by real-time PCR | ||
| 520 | |a RESULTS: A total of 113 mRNAs, 159 lncRNAs, 35 miRNAs, and 94 circRNAs were differentially expressed in ATO-treated mice myocardium. A lncRNA-circRNA co-regulation network was constructed. Function annotation revealed that aberrantly expressed genes may be enriched in the 'Wnt signaling pathway', 'Hippo signaling pathway', 'Notch signaling pathway', etc. Finally, the expression levels of Txnip and Spp1 were validated in ATO-treated cardiomyocytes, which was in accordance with the RNA-sequencing results | ||
| 520 | |a CONCLUSION: ATO altered coding and noncoding RNA profiles in myocardium of mice. The ATO-related lncRNA-circRNA co-regulation network was constructed. Genes in the co-regulation network are likely to play important roles in the cardiotoxicity of ATO. This study provides new insights into the prevention and treatment of ATO-induced cardiotoxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Arsenic trioxide | |
| 650 | 4 | |a Cardiotoxicity | |
| 650 | 4 | |a Noncoding RNA | |
| 650 | 4 | |a RNA sequencing | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Arsenic Trioxide |2 NLM | |
| 650 | 7 | |a S7V92P67HO |2 NLM | |
| 700 | 1 | |a Shen, Xiuyun |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Chaorun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhi, Fengnan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Chunpeng |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Yuqiu |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jincheng |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Desi |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Baofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Yunlong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 151(2022) vom: 21. Juli, Seite 113183 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2022 |g day:21 |g month:07 |g pages:113183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2022.113183 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2022 |b 21 |c 07 |h 113183 | ||